'Keytruda (pembrolizumab, MSD),' a cancer immunotherapy drug, will be considered for review by the Cancer Disease Review Committee this afternoon to discuss its expanding reimbursement.

Keytruda’s reimbursement expansion has been submitted to the Cancer Disease Review Committee three times, but it has received re-evaluation decisions each time.

Attention is being drawn to whether at least some of Keytruda’s indications will set reimbursement criteria, as this round of the Cancer Disease Review Committee will discuss the measure of the pharmaceutical company’s financial contribution.

According to industry sources on the 16th, Keytruda’s reimbursement expansion applica